Intraoperative challenges after induction therapy for non-small cell lung cancer: Effect of nodal disease on technical complexity

Hope A Feldman; Nicolas Zhou; Nathanial Deboever; Wayne Hofstetter; Reza Mehran; Ravi Rajaram; David Rice; Jack A Roth; Boris Sepesi; Stephen Swisher; Ara Vaporciyan; Garrett Walsh; Myrna Godoy; Chad Strange; Mara B Antonoff

doi:10.1016/j.xjon.2022.09.012

Intraoperative challenges after induction therapy for non-small cell lung cancer: Effect of nodal disease on technical complexity

JTCVS Open. 2022 Oct 25:12:372-384. doi: 10.1016/j.xjon.2022.09.012. eCollection 2022 Dec.

Authors

Affiliations

¹ Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.
² Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex.

Abstract

Objectives: Neoadjuvant therapy has been theorized to increase complexity of non-small cell lung cancer resections; however, specific factors that contribute to intraoperative challenges after induction therapy have not been well described. We aimed to characterize the effect of nodal involvement and nodal treatment response on surgical complexity after neoadjuvant therapy.

Methods: We identified patients treated with neoadjuvant therapy followed by anatomic lung resection for cN + non-small cell lung cancer between 2010 and 2020. Patients were categorized according to clinical N1 versus N2 disease. To evaluate the effect of nodal response to therapy, thoracic radiologists measured clinically suspected and pathologically involved lymph nodes before and after induction therapy. Operative reports were reviewed to identify technical challenges specifically related to nodal disease. Categorical outcomes were compared using Fisher exact test.

Results: One hundred twenty-four patients met inclusion criteria, among whom 107 (86.3%) were treated with neoadjuvant chemotherapy, whereas chemoradiation (n = 8) and targeted therapy (n = 9) were less common. In cases with N1 disease, 8/38 (21.0%) required proximal pulmonary arterial control, whereas this was necessary in only 2/88 (2.3%) of N2 cases (P = .001). Likewise, sleeve resection and arterioplasty were needed more frequently during resection of N1 disease (7/38, 18.4%) versus N2 disease (0/88, P < .001). Increased nodal response to therapy was associated with greater likelihood of requiring change in vascular approach (P = .011).

Conclusions: After induction therapy, N1 disease was associated with greater need for complex surgical maneuvers than N2 disease. Likewise, substantial treatment response was associated with increased intraoperative technical challenges. Recognizing such factors enables surgical teams to engage in appropriate operative planning to ensure patient safety.

Keywords: CT, computed tomography; EBL, estimated blood loss; IQR, interquartile range; NSCLC, non–small cell lung cancer; PA, pulmonary artery; PET, positron emission tomography; neoadjuvant therapy; nodal disease; non–small cell lung cancer; pulmonary artery; surgery.